• LAST PRICE
    7.0100
  • TODAY'S CHANGE (%)
    Trending Down-0.1800 (-2.5035%)
  • Bid / Lots
    7.0000/ 2
  • Ask / Lots
    7.5400/ 1
  • Open / Previous Close
    7.1000 / 7.1900
  • Day Range
    Low 6.8300
    High 7.1400
  • 52 Week Range
    Low 1.6100
    High 10.2400
  • Volume
    220,839
    above average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Thursday's close: 7.2
TimeVolumeMESO
09:32 ET30407.1
09:34 ET9817.07
09:36 ET9507.01
09:38 ET21327.03
09:39 ET33007.01
09:48 ET52696.97
09:50 ET5007.01
09:52 ET1007
09:54 ET8256.95
09:57 ET1006.965
09:59 ET41006.98
10:01 ET141717.08
10:06 ET31007.05
10:12 ET1007.09
10:14 ET9487.05
10:24 ET14007.11
10:28 ET1007.1
10:32 ET4007.128
10:35 ET2387.09
10:37 ET4007.1
10:39 ET2657.0801
10:50 ET2007.09
10:51 ET1007.09
10:57 ET2507.07
11:06 ET4007.01
11:08 ET5407.0492
11:09 ET3006.9701
11:11 ET3006.95
11:13 ET2006.9501
11:15 ET3006.962
11:18 ET2006.96
11:20 ET1006.95
11:22 ET3006.99
11:24 ET2006.99
11:26 ET1006.98
11:27 ET4006.96
11:29 ET1006.96
11:31 ET1006.96
11:33 ET25176.99
11:36 ET12406.96
11:38 ET28046.95
11:40 ET2006.93
11:42 ET31006.94
11:44 ET1006.91
11:47 ET3006.9
11:49 ET2006.9
11:51 ET8756.9453
11:54 ET2806.94
11:58 ET3916.94
12:00 ET6006.98
12:02 ET3006.96
12:03 ET2006.96
12:05 ET1006.94
12:07 ET7006.94
12:09 ET34396.9
12:12 ET2006.915
12:14 ET3006.905
12:16 ET5096.88
12:18 ET3006.88
12:20 ET9006.915
12:21 ET8006.9
12:23 ET1006.9
12:25 ET10206.89
12:27 ET1006.89
12:32 ET12796.91
12:34 ET2006.9
12:36 ET1006.9
12:39 ET3006.89
12:41 ET6186.89
12:43 ET1006.89
12:45 ET3006.885
12:48 ET1006.87
12:50 ET3006.87
12:52 ET2006.87
12:54 ET2006.87
12:57 ET31486.86
12:59 ET2006.83
01:01 ET8006.8725
01:03 ET24146.9
01:06 ET8006.92
01:10 ET3006.97
01:12 ET4006.99
01:14 ET2006.99
01:17 ET21017.05
01:24 ET10007.11
01:26 ET6007.08
01:28 ET1007.08
01:30 ET39057.075
01:32 ET1007.075
01:33 ET6007.08
01:35 ET1007.08
01:42 ET7007.1
01:46 ET4007.1
01:50 ET5007.1
01:51 ET18917.1
01:53 ET11847.1
01:55 ET2007.105
01:57 ET5947.09
02:00 ET24007.085
02:06 ET13007.1
02:15 ET1577.0996
02:18 ET37227.11
02:20 ET14007.1
02:24 ET14937.1
02:26 ET1127.0815
02:29 ET4607.1
02:31 ET3007.1
02:33 ET19007.1
02:36 ET68407.065
02:38 ET3007.09
02:40 ET1007.075
02:44 ET7007.075
02:47 ET21007.08
02:51 ET2267.0927
02:54 ET38597.11
03:00 ET9007.1
03:02 ET12387.1
03:03 ET20007.09
03:05 ET17827.1
03:07 ET36317.1
03:09 ET14997.1
03:12 ET50897.14
03:14 ET27537.1
03:16 ET20007.1
03:18 ET10127.1
03:20 ET27707.1
03:21 ET33777.11
03:23 ET20007.11
03:25 ET16007.11
03:27 ET18007.095
03:30 ET19977.1
03:32 ET19377.1
03:34 ET31837.1
03:36 ET36507.095
03:38 ET14987.095
03:39 ET36007.06
03:41 ET15007.05
03:43 ET19007.05
03:45 ET9007.05
03:48 ET9007.04
03:50 ET37077.05
03:52 ET11087.02
03:54 ET11417.02
03:56 ET25476.995
03:57 ET15096.99
03:59 ET37667.01
Data delayed at least 15 minutes.
0 New Today
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesMESO
Mesoblast Ltd
778.7M
-4.9x
---
United StatesMREO
Mereo BioPharma Group PLC
608.1M
-12.7x
---
United StatesSTOK
Stoke Therapeutics Inc
741.7M
-5.9x
---
United StatesDNTH
Dianthus Therapeutics Inc
749.3M
-8.0x
---
United StatesSPRY
ARS Pharmaceuticals Inc
791.6M
-15.7x
---
United StatesVRDN
Viridian Therapeutics Inc
802.2M
-2.8x
---
As of 2024-06-23

Company Information

Mesoblast Limited is an Australia-based is developing a range of late-stage product candidates derived from its proprietary mesenchymal lineage cell therapy technology platforms. The Company’s Remestemcel-L is mesenchymal lineage stromal cell product platform and is in late-stage development for treatment of systemic inflammatory diseases, including Pediatric steroid refractory acute Graft versus Host Disease (SR-aGVHD), acute respiratory distress syndrome (ARDS) and Biologic refractory inflammatory bowel disease. Its Rexlemestrocel-L is mesenchymal lineage precursor cell product platform and is in late-stage development for treatment of advanced chronic heart failure (CHF) and chronic low back pain (CLBP) due to degenerative disc disease. Two products are commercialized in Japan and Europe by the Company’s licensees, and it has a commercial partnership in Europe and China for certain Phase III assets.

Contact Information

Headquarters
L 38 55 Collins StMELBOURNE, VIC, Australia 3000
Phone
---
Fax
---

Executives

Non-Executive Independent Chairman of the Board
Jane Bell
Chief Executive Officer, Executive Director
Silviu Itescu
Non-Executive Independent Vice Chairman of the Board
William Burns
Interim Chief Financial Officer
Andrew Chaponnel
Chief Operating Officer
Dagmar Rosa-Bjorkeson

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$778.7M
Revenue (TTM)
$7.5M
Shares Outstanding
114.2M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
3.48
EPS
$-1.44
Book Value
$12.34
P/E Ratio
-4.9x
Price/Sales (TTM)
104.3
Price/Cash Flow (TTM)
---
Operating Margin
-735.47%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.